Azulfidine en-tabs and Death - a phase IV clinical study of FDA data

Summary:

Death is reported as a side effect among people who take Azulfidine en-tabs (sulfasalazine), especially for people who are male, 60+ old, also take Prednisolone, and have High blood pressure.

The study is created by eHealthMe based on reports of 2,198 people who have side effects when taking Azulfidine en-tabs from the FDA, and is updated regularly.

What is Azulfidine en-tabs?

Azulfidine en-tabs has active ingredients of sulfasalazine. It is often used in rheumatoid arthritis. eHealthMe is studying from 2,220 Azulfidine en-tabs users. Check the latest studies of Azulfidine en-tabs.

On Jul, 24, 2026

2,198 people reported to have side effects when taking Azulfidine en-tabs.
Among them, 16 people (0.73%) died.

Among these 16 people:

What is the gender of people who died when taking Azulfidine en-tabs? *

female: 50 %
male: 50 %

What is the age of people who died when taking Azulfidine en-tabs? *

What are other drugs people take besides Azulfidine en-tabs? *

What are other side effects people have before they died? *

Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 2 people, 12.50%
Viral Infection: 1 person, 6.25%
Disease Progression: 1 person, 6.25%
Heart Disease: 1 person, 6.25%
Headache (pain in head): 1 person, 6.25%
Gastric Ulcer (stomach ulcer): 1 person, 6.25%
Fever: 1 person, 6.25%
Fatigue (feeling of tiredness): 1 person, 6.25%
Drug Eruption (adverse drug reaction of the skin): 1 person, 6.25%
Cholestasis (a condition where bile cannot flow from the liver to the duodenum): 1 person, 6.25%

What are the existing conditions these people have? *

Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 2 people, 12.50%
Cardiac Failure: 2 people, 12.50%
High Blood Pressure: 2 people, 12.50%
Type 2 Diabetes: 1 person, 6.25%
Hyperuricaemia (level of uric acid in the blood that is abnormally high): 1 person, 6.25%
Back Pain: 1 person, 6.25%
Chronic Kidney Disease: 1 person, 6.25%
Dyslipidaemia (abnormal amount of lipids): 1 person, 6.25%
Gastritis - Chronic (long lasting inflammation of stomach): 1 person, 6.25%
Hypercalcaemia (elevated calcium (ca+) level in the blood): 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Azulfidine en-tabs:

Azulfidine en-tabs (2,220 reports)

Expand to all the drugs that have ingredients of sulfasalazine:

Death and drugs with ingredients of sulfasalazine (927 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Azulfidine en-tabs:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Death:

Death (3,120 drugs)

Browse all the conditions that are associated with Death:

Death (3,686 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on sulfasalazine (the active ingredients of Azulfidine en-tabs) and Azulfidine en-tabs (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.